• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma.

作者信息

Zanwar Saurabh, Ravindran Aishwarya, Abeykoon Jithma P, Young Jason R, Kozelsky Timothy F, Rech Karen L, Goyal Gaurav, Go Ronald S

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN.

Division of Hematopathology, Department of Laboratory Medicine and Pathology; Mayo Clinic, Rochester, MN.

出版信息

Haematologica. 2022 Sep 1;107(9):2276-2279. doi: 10.3324/haematol.2022.280948.

DOI:10.3324/haematol.2022.280948
PMID:35615932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9425309/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9425309/82fa9851135b/1072276.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9425309/93a868146903/1072276.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9425309/82fa9851135b/1072276.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9425309/93a868146903/1072276.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7974/9425309/82fa9851135b/1072276.fig2.jpg

相似文献

1
Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma.帕博利珠单抗联合放射治疗使一名多系统朗格汉斯细胞肉瘤患者获得长期缓解。
Haematologica. 2022 Sep 1;107(9):2276-2279. doi: 10.3324/haematol.2022.280948.
2
Langerhans cell sarcoma: case report and review of world literature.朗格汉斯细胞肉瘤：病例报告及世界文献综述
J Pediatr Hematol Oncol. 2014 Aug;36(6):419-25. doi: 10.1097/MPH.0000000000000196.
3
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.帕博利珠单抗治疗晚期软组织肉瘤和骨肉瘤（SARC028）：一项多中心、双队列、单臂、开放标签的2期试验。
Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4.
4
[Long-term remission of Langerhans cell sarcoma by AIM regimen combined with involved-field irradiation].[AIM方案联合受累野照射实现朗格汉斯细胞肉瘤长期缓解]
Rinsho Ketsueki. 2012 Nov;53(11):1911-5.
5
Langerhans cell sarcoma: a systematic review.朗格汉斯细胞肉瘤：系统评价。
Cancer Treat Rev. 2015 Apr;41(4):320-31. doi: 10.1016/j.ctrv.2015.02.011. Epub 2015 Mar 9.
6
[Durable remission of Langerhans cell sarcoma attained by autologous hematopoietic stem cell transplantation following surgical resection].[手术切除后通过自体造血干细胞移植实现朗格汉斯细胞肉瘤的持久缓解]
Rinsho Ketsueki. 2019;60(4):314-318. doi: 10.11406/rinketsu.60.314.
7
Langerhans cell sarcoma of the head and neck.头颈部朗格汉斯细胞肉瘤
Crit Rev Oncol Hematol. 2016 Mar;99:180-8. doi: 10.1016/j.critrevonc.2015.12.017. Epub 2016 Jan 2.
8
Langerhans Cell Histiocytosis and Langerhans Cell Sarcoma: Current Understanding and Differential Diagnosis.朗格汉斯细胞组织细胞增多症和朗格汉斯细胞肉瘤：当前认识与鉴别诊断
J Clin Exp Hematop. 2016;56(2):109-118. doi: 10.3960/jslrt.56.109.
9
[Langerhans cell sarcoma: a case report and literature review].[朗格汉斯细胞肉瘤：一例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2012 Apr;33(4):266-9.
10
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.既往放疗与帕博利珠单抗治疗非小细胞肺癌的临床活性及毒性：KEYNOTE-001 1期试验的二次分析
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.

引用本文的文献

1
Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France.法国141例恶性组织细胞增多症回顾性系列研究的特征及治疗结果
Blood Adv. 2025 May 27;9(10):2530-2541. doi: 10.1182/bloodadvances.2024015208.
2
Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis.恶性组织细胞增生症的临床特征、分子异常、治疗方法和结局。
Am J Hematol. 2024 May;99(5):871-879. doi: 10.1002/ajh.27263. Epub 2024 Feb 26.
3
Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report.

本文引用的文献

1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
2
Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of Reported Cases.免疫治疗时代放疗的远隔效应：已报道病例的系统评价
Cureus. 2019 Feb 20;11(2):e4103. doi: 10.7759/cureus.4103.
3
免疫检查点抑制剂治疗组织细胞肉瘤患者的良好预后：一例报告
Ann Med Surg (Lond). 2023 Nov 1;85(12):6274-6278. doi: 10.1097/MS9.0000000000001446. eCollection 2023 Dec.
Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States.
美国朗格汉斯细胞肉瘤的发病率、临床特征和结局。
Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):441-446. doi: 10.1016/j.clml.2019.03.026. Epub 2019 Apr 1.
4
Langerhans cell sarcoma arising from antecedent langerhans cell histiocytosis: A case report.源于既往朗格汉斯细胞组织细胞增多症的朗格汉斯细胞肉瘤：一例报告。
Medicine (Baltimore). 2019 Mar;98(10):e14531. doi: 10.1097/MD.0000000000014531.
5
Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.组织细胞肿瘤中的肿瘤突变负荷及其他预测性免疫治疗标志物
Blood. 2019 Apr 4;133(14):1607-1610. doi: 10.1182/blood-2018-12-893917. Epub 2019 Jan 29.
6
Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.曲美替尼治疗伴有激活型MAP2K1（MEK1）突变的组织细胞肉瘤
N Engl J Med. 2018 May 17;378(20):1945-1947. doi: 10.1056/NEJMc1511490.
7
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
8
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.程序性细胞死亡1配体（PD-L1和PD-L2）在组织细胞和树突状细胞疾病中的表达
Am J Surg Pathol. 2016 Apr;40(4):443-53. doi: 10.1097/PAS.0000000000000590.
9
Langerhans cell sarcoma: a systematic review.朗格汉斯细胞肉瘤：系统评价。
Cancer Treat Rev. 2015 Apr;41(4):320-31. doi: 10.1016/j.ctrv.2015.02.011. Epub 2015 Mar 9.
10
Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.BRAF V600E 突变的原发性中枢神经系统组织细胞肉瘤对维莫非尼的显著反应。
Neurology. 2014 Oct 14;83(16):1478-80. doi: 10.1212/WNL.0000000000000880. Epub 2014 Sep 10.